Indeed, the need for new biomarkers of inflammation in asthma has been highlighted in a recent study of an IL-13 neutralising monoclonal antibody (Brightling et al., 2015), where measurement of airway IL-13 levels might be a more relevant biomarker than blood eosinophils and serum periostin. Here, IL13 is linked to asthma.